Thought Leadership
Email Page
2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
April 17, 2018
Jonathan Harris, Drew Hillier, and Ross Blau
Westlaw Journal

Axinn partner Jonathan Harris and associates Drew Hillier and Ross Blau's article, "2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways" was published by Westlaw Journal Medical DevicesWestlaw Journal Products LiabilityWestlaw Journal Health LawWestlaw Journal Pharmaceutical and Westlaw Journal Intellectual Property. The article discusses nuanced shifts in Federal Circuit opinions and the lessons that can be gleaned from them.

Click here to access the article.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.